



# Rabies - An Update

Tarun Kumar Dutta\*, LH Gotekar\*\*,  
Ratnakar Sahoo\*\*\*

\*Professor, \*\*Professor (on deputation to Nepal), \*\*\*Assistant Professor,  
Department of Medicine,  
Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry.

137

## A B S T R A C T

The principle of approach to rabies has not changed, but there has been significant modification, more so in diagnosis and prophylaxis with better understanding of modes of transmission of disease, incubation period and knowledge of chronic excretors of rabies virus. Bat-transmitted rabies, graft rabies and rabies by inhalation are well-known entities now. New bat-transmitted *Lyssaviruses* (rabies-related viruses) have been implicated in causation of rabies in UK and Australia, countries considered to be free of rabies. Bat-transmitted rabies is emerging as a major threat in developed world. Extended incubation period upto 7 years is a startling observation, warranting any unexplained neuropsychiatric manifestation in an endemic area to be investigated for rabies. Dogs outliving victims are being reported. Earlier antemortem diagnosis by RT-PCR test and nuchal skin biopsy are path-breaking advances. Tissue culture vaccines replacing nerve tissue vaccines, even in developing countries including India is heartening news. Possible cheaper alternative to human rabies immunoglobulin (HRIG) in form of a 'cocktail of monoclonal antibodies' is being worked out. Nevertheless, survival in rabies still remains a mirage, with only a handful of recovery notwithstanding permanent neurological sequelae.

### INTRODUCTION

Rabies is an ancient disease, which still strikes terror in much of the developing world. Much of the terror derives from the inexorable death that follows after the development of symptoms and the long incubation period that leaves dangling the risk of rabies for months and even years. The principle of approach to rabies has not changed, but there has been significant modification, more so in diagnosis and prophylaxis with better understanding of disease. Survival in rabies still remains a mirage, with only a handful of recovery notwithstanding permanent neurological sequelae.<sup>1</sup>

### MODES OF TRANSMISSION

Though dog bite is the commonest mode of transmission, there are various other modes of transmission of rabies.<sup>2</sup> (Fig. 1)

#### Incubation Period

Generally: 20-60 days<sup>15</sup>

Range: 7 days – 1 year

Uncommonly:

- i. Minimum 5 days<sup>15</sup>

- ii. Maximum upto 7 years<sup>15</sup> (Extended incubation period): 11 months to 6 years of incubation period reported among three immigrants to USA<sup>16</sup>

#### Carrier State in Animals

Dog outliving man: Some reports are there in India<sup>17,18</sup>

Chronic carrier state in animals:<sup>1</sup>

- Observed in healthy vector species e.g. mongoose, skunks, raccoon, fox, jackal
- Bats: observed among vampire, insectivorous and fruit-bats
- Domestic dogs (among those in Ethiopia and rarely in India: *one chronic excretor of virus in saliva for 30 months reported from India*<sup>18</sup>)
- Oulou fato: a type of dog rabies with virus of low pathogenicity: prolonged survival of dog occurs (observed in SubSaharan Africa)

#### CLINICAL FEATURES

Encephalitic and paralytic types of presentation:

Encephalitic form (furious rabies): Classical presentation of hydrophobia with or without aerophobia / photophobia (in absence of coma at onset)



**Table 2: Tissue Culture Vaccines Currently Available in India<sup>25</sup>****First generation:**

Human diploid cell vaccine (HDCV) – One dose: 1 ml (IM)\*, 0.1 ml (ID)\*\*

**Second generation:**

Purified chick embryo cell vaccine (PCECV) - One dose: 1 ml (IM), 0.1 ml (ID)

Purified vero cell rabies vaccine (PVRV) – One dose: 0.5 ml (IM), 0.1 ml (ID)

\*IM - Intramuscular \*\*ID - Intradermal

**PROPHYLAXIS****Animal prophylaxis**

There is a current WHO initiative in Asia in this regard. Rabies in stray dogs can be reduced by vaccination, fertility control and clearing rubbish to reduce food supply.<sup>24</sup>

Vaccination of wildlife vectors with oral live attenuated rabies virus or vaccinia-recombinant vaccines has virtually eliminated fox rabies in West Europe.<sup>1</sup>

**Human prophylaxis:** (Tables 2, 3)

I. Pre-exposure prophylaxis: Indicated for high risk persons

II. Post-exposure prophylaxis:

Optimal prophylaxis consists of the following.

- i. Thorough local cleansing of wound with soap and water
- ii. Active immunization
- iii. Administration of rabies immunoglobulin (RIG), as and when indicated

Tissue culture vaccine (TCV) has almost replaced nerve tissue vaccine for inducing active immunization (Table 2).

Intradermal recommendation by WHO is a newer attempt to have effective antibody titre against rabies with a lower total requirement of vaccine. The principles that allow intradermal vaccination are the better response to an equal volume of antigen when placed in contact with Langerhan's cells of the epidermis and use of multiple sites of vaccination to obtain maximum drainage of antigen-presenting cells to lymph nodes. The intradermal regimens have had remarkable success in Thailand. However, some expertise is necessary for correct intradermal administration.<sup>15, 26</sup>

Human RIG (20 IU/kg of body weight) is prohibitively costly. A 'cocktail of monoclonal antibodies' already being investigated could begin to address the crisis in global supply of RIG and the expenditure involved in procuring it.<sup>1, 27</sup>

**Vaccine failure:**<sup>15</sup>

Needless to say, it should be viewed seriously, since vaccine failure means certain death. Common causes of vaccine failure are as below.

- i. Late starting of prophylaxis
- ii. Insufficient cleaning of wound

**Table 3: Regimens for pre- and post-exposure vaccination<sup>15</sup>**

Vaccination, route	Day (one dose given)*
<b>Preexposure:</b>	
IM	0, 7, & 21 (or 28)
ID	0, 7, & 21 (or 28)
<b>Postexposure:</b>	
IM	0, 3, 7, 14 and 28
ID**	0 (8 doses), 7 (4 doses), 28 and 90
<b>Reexposure (Booster dose):</b>	
IM	0 & 3
ID	0 & 3

\* Multiple doses given, where specified

\*\* Used with HDCV, PCECV only

- iii. Omission of RIG in severe cases of dog-bite like on face, head and neck
- iv. Failure to inject RIG into all wound sites (latest recommendation is to inject maximum RIG locally, not 50% of total as earlier practiced)
- v. Suturing of wounds (should be avoided till after 24-48 hours of bite and done only after RIG infiltration locally)
- vi. TCV injected in gluteal region (ideal deltoid region in adults and anterolateral thigh in children, in view of erratic absorption from gluteal region)
- vii. Concomitant use of immunosuppressants like chloroquine/prednisolone (warrants doubling of 1<sup>st</sup> dose of TCV; intradermal administration of TCV may also result in treatment failure in such situation)

**MANAGEMENT OF CLINICAL RABIES<sup>15, 28</sup>**

To date, there are only five survivors of rabies, including a six year old girl from India.<sup>1</sup> All of them had received some rabies vaccine before the onset of illness and all had paralytic rabies. All, except one, had residual neurologic deficit. Three had profound neurological sequelae i.e., had "limited survival".<sup>1</sup> The approach to management of rabies should be palliative. In unusual circumstance, if a patient has arrived early, a decision may be made to use an aggressive approach. No single therapeutic agent is likely to be effective. A combination of rabies vaccine, RIG, monoclonal antibodies, ribavirin, interferon- $\alpha$  and ketamine (anaesthetic drug which has been demonstrated to inhibit in-vitro replication of virus) may be tried.<sup>23, 28</sup> Corticosteroids should not be used. Relatives should be clearly made aware that intensive care treatment may only prolong life; there should be no expectation of survival in unvaccinated patient, and previously immunized patient may have "limited survival", if recovers.<sup>1</sup>

**EPIDEMIOLOGICAL ISSUES<sup>1</sup>**

Principal animal vectors of rabies virus in various countries are given in Table 4.

Rabies virus is only one of a number of lyssaviruses enzootic in bats. Rabies virus, a single stranded RNA virus was the first of seven lyssavirus genotypes to be identified.

Two newly discovered lyssaviruses (rabies-related viruses) have been identified in Australia (Australian bat lyssavirus [ABLV]) and United Kingdom (European bat lyssavirus [EBLV]),

**Table 4 : Principal Animal Vectors of Rabies**

Country*	Host
India	Dog
USA	Insectivorous bat
Europe	Fox
Latin America	Vampire bat

\* Rabies-free countries - UK, Japan, Antarctica, Australia & New Zealand (Australasia)

countries considered to be free of rabies. Insectivorous bat is responsible for recent reports of rabies in both the countries, by above-mentioned rabies-related viruses (RRV). Disease caused by these viruses has no distinctive feature (furious, paralytic and atypical features all reported).<sup>1</sup> Fortunately conventional post-exposure prophylaxis with TCV is also found effective against these viruses.<sup>15</sup> Oral vaccination of foxes has controlled rabies in West Europe; but bat rabies has emerged as a newer problem in developed world and there is no way bats can be vaccinated.

**Acknowledgement:** I am deeply indebted to my father, Dr. J.K. Dutta, former Medical Superintendent, Infectious Diseases' Hospital, Delhi for inspiring and guiding me into field of rabies.

## REFERENCES

- Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. *Lancet* 2004;363:959-69.
- Dutta JK, Dutta TK, Das AK. Human rabies: Modes of transmission. *J Assoc Physicians India* 1992;40:322-4.
- Constantine DG. Rabies transmission by non-bite route. *Public Health Report* 1962;77:287-9.
- Winkler WG. Air-borne rabies virus isolation. *Bull Wildlife Disease* 1968; 4:37-40
- Winkler WG, Fashinell TR, Liffingwell L, Howard P, Conomy JP. Airborne rabies transmission in a laboratory worker. *JAMA* 1973;226:1219-21.
- Tillotson JR, Axelord D, Lyman DO. Centers for Disease Control. Rabies in a laboratory worker. *MMWR* 1977;26:183-4.
- Tierkel ES. Rabies. In: Hall TG, ed. Diseases transmitted from animal to human. Springfield, Illinois: Thomas. 1963:293-7.
- Dutta JK, Dutta TK. Rabies transmission by oral and other non-bite routes (Editorial). *J Indian Med Assoc* 1998;96:359.
- Houff SA, Burton RC, Wilson RW, Henson TE, London WT, Baer GM, et al. Human-to-human transmission of rabies by corneal transplant. *NEJM* 1979;300:603-4.
- Gode GR, Bhide NK. Two rabies deaths after corneal graft from one donor. *Lancet* 1988;ii:791.
- Pompoukis PS. Rabies by human bite. *Ann de l'institute Pasteur* 1900;14: 111.
- Sipahioglu U, Alpaut S. Transplacental rabies in human (abstract). *Mikrobiyol Bul* 1985;19:95-9.
- Dutta JK. Bat-transmitted rabies: the global scene. *J Assoc Physicians India* 1997;45:873-5.
- Dutta JK. Human rabies by cryptic exposure: A challenge to clinicians. In: Thakur BB ed. API Medicine Update, Mumbai 2000;10:719-22.
- Plotkin SA. Rabies. *Clin Infect Dis* 2000;30:4-12.
- Smith JS, Fishbein DB, Rupprecht CE, Clark K. Unexplained rabies in three immigrants in United States: A virological investigation. *NEJM* 1991;324:205-11.
- Charan VD. Rabies: an unusual observation. *J Assoc Physicians India* 1987; 35:393-4.
- Veeraraghavan N. Studies on the salivary excretion of rabies virus by the dog from Surandai. Coonoor: Pasteur Institute of South India. 1987:66.
- Dutta JK, Dutta TK. Uncommon manifestations of rabies in man. *J Intern Med* 1994;Suppl 7:32-33.
- Kewal K, Dutta JK. Human rabies in Delhi. *Ind J Public Health* 1978;22: 259-64.
- Dutta JK. Priapism in rabies. *J Assoc Physicians India* 1992;40:555.
- Prabhakar S, Malhotra RM, Goel DS. Rabies presenting as catatonic stupor. *J Assoc Physicians India* 1992;40:272-3.
- Dutta JK, Dutta TK. Treatment of clinical rabies in man: drug therapy and other measures. *Internat J Clin Pharmacol and Ther* 1994;32:594-7.
- Wandeler AI, Matter HC, Kappeler A, Budde A. The ecology of dogs and canine rabies: a selective review. *Rev Sci Tech* 1993;12:51-71.
- Dutta TK, Ghotekar LH. Prevention of rabies. In: Thakur BB ed. API Medicine Update, Mumbai 2000;10:473-9.
- Dutta JK, Dutta TK. Rabies in endemic countries (Editorial). *BMJ* 1994; 308:488-9.
- Prośniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. *The J Infect Dis* 2003;187:53-6.
- Jackson AC, Warrell MJ, Rupprecht CE, Ertl HCJ, Dietzschold B, O'Reilly M et al. Management of rabies in humans. *Clin Infect Dis* 2003;36:60-3.